Assistant Professor, Department of Hematology/Oncology
Thoracic Oncology Program
Lung Cancer, Thymoma, Mesothelioma, Lung Metastases
I believe in treating the patient as a whole. This includes offering cutting edge treatment strategies for their disease but also focusing on the psychological and social needs of the person with the disease. I strive to offer the best treatment possible by working with my colleagues from the fields of medical, radiation and surgical oncology who also focus on lung cancer treatment. The benefit of being treated at an academic center like Fox Chase is access to innovative treatment strategies being tested on clinical trials, which allows us to offer therapies prior to their FDA approval. I spend the time to educate my patients and their families, to the extent my patients are comfortable, on their disease and the potential treatment options. I want all of my patients to feel empowered to be active participants in their care, and work with me to decide on the best, personalized, treatment plan.
Judd J, Dulaimi E, Li T, Millenson MM, Borghaei H, Smith MR, Al-Saleem TI. Low level of blood CD4+ T cells is an independent predictor of inferior progression-free survival in diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma and Leukemia 2017; 17 (2): 83 – 88.
Judd J, Zibelman MR, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman JR, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is). The Oncologist 2017; 22 (10): 1232-1237.
Judd J, Borghaei H. Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer. Review. Thoracic Surgery Clinics 2020, Volume 30 (2): 199 – 206.
Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13. PMID: 34518295; PMCID: PMC9662933.
Harrison S, Judd J, Chin S, Ragin C. Disparities in Lung Cancer Treatment. Curr Oncol Rep. 2022 Feb;24(2):241-248. doi: 10.1007/s11912-022-01193-4. Epub 2022 Jan 26. PMID: 35080738; PMCID: PMC8965800.
Judd, J. Physician-patient communication and the use of over-the-counter medication and supplements by patients with gynecologic cancer undergoing chemotherapy. Oral presentation. Society of Gynecologic Oncology, Hot Springs, VA, October 2009
Judd, J. Physician-patient communication and the use of over-the-counter medication and supplements by patients with gynecologic cancer undergoing chemotherapy. Poster presentation. Society of Gynecologic Oncology, San Francisco, CA, March 2010
Al-Saleem TI, Dulaimi E, Millenson MM, Smith MR, Judd J, Li T, Borghaei H. Low blood absolute CD4 counts is associated with inferior progression free survival in diffuse large B-cell lymphoma independent of age and IPI. Blood, December 2014, 124 (21) 5420
Judd J, Zibelman MR, Handorf E, O'Neill J, Bentota S, Doyle J, Uzzo RG, Bauman JR, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is). Poster presentation. American Society of Clinical Oncology, Chicago, IL, June 2016
Zibelman MR, Judd J, Handorf E, O’Neill J, Bentota S, Doyle J, Uzzo RG, Bauman JR, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Association of eosinophilia with efficacy in non-melanoma patients treated with programmed death 1 inhibitors. Poster presentation. American Society of Clinical Oncology, Chicago, IL, June 2016.
Judd J, Ramamurthy C, Handorf E, Borghaei H, Geynisman DM, Zibelman M, Bauman J. Response and Adverse Events to Chemotherapy After Prior Checkpoint Inhibition in Lung Cancer. Poster presentation. American Society of Clinical Oncology – Society for Immunotherapy of Cancer Symposium, San Francisco, CA, January 2018.
Liu SV, Vanderwalde AM, Mamdani H, Raez LE, Baca Y, Xiu J, Wolfgang MK, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Chul K, Antoinette WJ, Chukwuemeka I, Lopes G, Spira AI, Judd J, Kim E, Borghaei H. Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC). Poster presentation. American Society of Clinical Oncology, June 2020.
Judd J, Handorf E, Gupta B, Edelman MJ. Analysis of first-line treatment (tx) patterns in advanced non-small cell lung cancer (NSCLC) patients (pts) with compromised performance status (PS), organ dysfunction (dfxn) or other significant comorbidities. Online Publication. American Society of Clinical Oncology, June 2021.
Naqash AR, Floudas CS, Maoz A, Xiu J, Baca Y, Zeng J, Kim C, Judd J, Nieva J, Borghaei H, Takebe N, Liu SV, Mamdani H. Influence of TP53 co-mutation on the tumor microenvironment (TME) in STK11-mt Non-Small Cell Lung Cancer (NSCLC). Poster Presentation. American Society of Clinical Oncology, June 2021.
Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13. PMID: 34518295; PMCID: PMC9662933.
Zarrabi KK, Galloway TJ, Flieder DB, Kumar SS, Judd J, Bauman JR. Assessing plasma circulating tumor human papillomavirus (HPV) DNA in determining treatment response in HPV-associated oropharyngeal cancer. Head Neck. 2022 Aug;44(8):E25-E30. doi: 10.1002/hed.27081. Epub 2022 May 12. PMID: 35546490.
Patient comments